BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Del Campo M, Zetterberg H, Gandy S, Onyike CU, Oliveira F, Udeh-Momoh C, Lleó A, Teunissen CE, Pijnenburg Y. New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimers Dement 2022. [PMID: 35235699 DOI: 10.1002/alz.12643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Cousins KAQ, Shaw LM, Chen-Plotkin A, Wolk DA, Van Deerlin VM, Lee EB, McMillan CT, Grossman M, Irwin DJ. Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers. JAMA Neurol 2022. [PMID: 36215050 DOI: 10.1001/jamaneurol.2022.3265] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Bolsewig K, Hok-a-hin Y, Sepe F, Boonkamp L, Jacobs D, Bellomo G, Paoletti FP, Vanmechelen E, Teunissen C, Parnetti L, Willemse E, Platt B. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias. JAD 2022. [DOI: 10.3233/jad-220318] [Reference Citation Analysis]
3 Endres D, Schlump A, Nickel K, Berger B, Runge K, Lange T, Domschke K, Urbach H, Venhoff N, Meyer PT, Brumberg J, Prüss H, Tebartz van Elst L. Frontotemporal dementia associated with intrathecal antibodies against axon initial segments. Alzheimers Dement 2022. [PMID: 36086913 DOI: 10.1002/alz.12780] [Reference Citation Analysis]